EGFR and non-small cell lung carcinoma: In the context of unresectable stage III epidermal growth factor receptor (EGFR)-positive NSCLC, the LAURA trial demonstrated a striking improvement in progression-free survival with osimertinib following chemoradiotherapy (CRT), 39.1 months versus 5.6 months with placebo [22].